Fenwick & West advised Freenome on the deal.Freenome, a privately held biotechnology company, announced its $300million Series D financing. The round was led by investors Perceptive Advisors…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
